Press Releases

 Mar 02, 2023, 07:30 ET  Oral PL8177 is gut restricted in rats, dogs and humans Bioinformatics data shows positive effects on enterocytes and infiltrating immune cells CRANBURY, N.J., March 2, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers in …

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease Read More »

 Feb 28, 2023, 07:30 ET  CRANBURY, N.J., Feb. 28, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled “Use of Bremelanotide in …

Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension Read More »

 Feb 15, 2023, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results Currently Expected Mid-Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced First Patient Dosed Planned Interim Analysis Targeted for First Half Calendar Year 2023 Topline Results Currently Expected …

Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Read More »

 Feb 10, 2023, 07:30 ET  CRANBURY, N.J., Feb. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its …

Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023 Read More »

 Jan 19, 2023, 07:30 ET  –  BREAKOUT Study is Palatin’s third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists –  Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J., Jan. 19, 2023 …

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease Read More »

 Jan 18, 2023, 07:30 ET  Sells Net Operating Loss Tax Benefits Through New Jersey Economic Development Program CRANBURY, N.J., Jan. 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has received approximately $4.7 …

Palatin Receives $4.7 Million of Non-Dilutive Funding Read More »

 Jan 10, 2023, 07:30 ET  –  Collaboration with The William Harvey Research Institute and Queen Mary University of London –  PL-8177 displayed pro-resolving and anti-arthritic effects in rodents CRANBURY, N.J., Jan. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers …

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions Read More »

 Jan 05, 2023, 07:30 ET  15.4% increase in net product revenue over the prior quarter 1,290% increase over the comparable quarter in 2021 11.5% increase in prescriptions dispensed over the prior quarter Increased 134% over the comparable quarter in 2021 CRANBURY, N.J., January 5, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical …

Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results Read More »

 Nov 14, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Net Product Revenue Increased 13% and Prescriptions Dispensed Increased 17%, Over the Prior Quarter Prescription Refills Exceed 50% …

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Read More »

 Nov 09, 2022, 17:16 ET  CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive …

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022 Read More »